![]() ![]() Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. This indication was approved by the US Food and Drug Administration (“FDA”) under accelerated approval based on overall response rate and duration of response. In the United States, DANYELZA® (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. MSK has institutional financial interests related to the compound and Y-mAbs. Researchers at Memorial Sloan Kettering Cancer Center (“MSK”) developed DANYELZA, which is exclusively licensed by MSK to Y-mAbs. We continue to focus on expansion of DANYELZA in other jurisdictions, working to provide access to children living with refractory or relapsed neuroblastoma,” said Thomas Gad, founder, President and Interim CEO. It’s very exciting to see this treatment approved, creating access to DANYELZA in Brazil from the joint efforts by our partner Adium and the development team at Y-mAbs. “Today is an important day for children living with refractory/relapsed high-risk neuroblastoma in Brazil. DANYELZA is administered to patients three times in a week and the treatment is repeated every four weeks. (“Adium”).ĭANYELZA is a recombinant humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. DANYELZA will be marketed in Brazil by Y-mAbs’ partner Adium Pharma S.A. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (“Anvisa”) has granted marketing authorization for DANYELZA (naxitamab-gqgk) 40mg/10mL injection. So Suggest You Follow adium pharma s.a., At The Same Time, Mark This Company's Industry And Products, It Will Help You Receive More Accurate Data Push.NEW YORK, (GLOBE NEWSWIRE) - Y-mAbs Therapeutics, Inc. That Including Email And Have Transaction Recently Will Be Pushed. Through Big Data, Recommend The Company That Buying Or Supplying The Same Product (Or HS Code) From The Peru's Buyer Company Database. Help You Deeply Analyze The Target Market, And Scientifically Formulate Production And Marketing Strategies.īesides, We Are Trying Our Best To Provide Accurate Target Customers Recommend. It Can Calculate The Main Market And Occupation Of adium pharma s.a. Through Summary Statistics Of Transaction,We Extract This Company's Data Of Import-Export Ports And Trade Area, And Then You Can Check Related Data. This Data Will Help You Study Your Competitors, Maintain And Monitor Your Customers, And Develop Target Users. While You Can Check Product Type, Quantity, Price, And Trade Frequency Of Each Transaction. You Can Screen Companies By Transactions, Trade Date, And Trading Area. We Extract The Trade Partners From adium pharma s.a.'S 9183 Transctions. If There Is New Transactions, We Will Also Inform You By The System. Follow Up The Company, And Then Can Export This Company's Contact And B/Ls. Official Reference Contact Is From Peru Original Bill Of Ladings, Including Email, Phone, Fax, Address, And Official Website. This Company's Trade Report Mainly Contains Market Analysis, Contact, Trade Partners, Ports Statistics, And Trade Area Analysis. Buyers adium pharma s.a.ĪMLODIPINA BESILATO + OLMESARTAN (5 MG + 20 MG) X 7 COMPĪMLODIPINA BESILATO + OLMESARTAN (5 MG + 40 MG) X 7 COMPĪMLODIPINA BESILATO + OLMESARTAN (5 MG + 20 MG) X 28 COMPĪTORVASTATINA + EZETIMIBE (20 MG + 10 MG) X 30 COMPĪMLODIPINA BESILATO + OLMESARTAN (10 MG + 40 MG) X 28 COMPĪdium pharma s.a. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |